• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

First national follow-on study to EPAD LCS launches

2022-04-07News

We are delighted to announce that the first study participant for the EPAD Scotland study was seen today at the University of Edinburgh in the UK. The EPAD Scotland study is the first follow-on study to the large pan-European EPAD Longitudinal Cohort Study (LCS) which finished study visits in 2020.

The European Prevention of Alzheimer’s Dementia (EPAD) LCS was a pan-European study with an aim to identify the very earliest signs of Alzheimer’s disease years before any clinical symptoms manifest. As part of the EPAD LCS, over 2,000 participants were screened and a wide range of cognitive, clinical, neuroimaging and biomarker data collected. All the EPAD LCS data is open access and available through data access request here.

Since the end of the overall Innovative Medicine’s Initiative funding of EPAD LCS, there are follow-on studies to the EPAD LCS being set up locally within each host country in order to continue collecting longitudinal data on early risk factor for dementia. EPAD LCS continues to be one of the largest cohorts of participants in the pre-dementia stages and will be further enhanced with local follow-on studies inviting the same participants back to continue building up longitudinal data over many years. The EPAD Scotland study is the first national initiative to have started study recruitment.

The primary investigator for the EPAD Scotland study is Prof Craig Ritchie and the study is funded by the Alzheimer’s Disease Discovery Fund.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
New paper on the affordances of clinical research participation
2022-01-14
ADDI celebrates one year of achievements
2021-11-17
EPAD announces a new collaboration with Hummingbird Diagnostics
2021-10-19
Latest News
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
    2022-03-10
  • New paper on the affordances of clinical research participation
    2022-01-14
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Registration is now open for the upcoming #NeuroToolKit Data Hackathon! Join fellow experts and investigate biomarkers in #Alzheimers disease. You'll work with @IMI_EPAD datasets by utilizing @AlzData resources. For more information: ep-ad.org/addi-neurotool… twitter.com/IMI_EPAD/statu…

reply retweet favorite
6:56 am · 2022-05-18
Twitter
EPAD
EPAD
@IMI_EPAD

📢 Four abstracts with @IMI_EPAD data have been accepted for #AAIC22, including 3 posters & 1 oral presentation! Looking forward to meeting you in San Diego! @LuigiLorenzini1 @GregorySarah @fpmaragall @amsterdamumc @CenDemPrevent twitter.com/alzassociation…

reply retweet favorite
10:45 am · 2022-04-28
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Research Participant Panel has been established to give participants an active role in influencing the design, conduct and reporting of research. Want to know more? Watch this recording. #31AEC @AlzheimerEurope @IMI2_NEURONET @CenDemPrevent youtu.be/GObdDorTOE0?t=…

reply retweet favorite
6:42 am · 2022-04-20
Twitter
EPAD
EPAD
@IMI_EPAD

Listen to @GregorySarah from @CenDemPrevent talking about the associations between stressful life events, #Alzheimer's disease biomarkers and cognition in the @IMI_EPAD Longitudinal Cohort Study at the @AlzheimerEurope conference #31AEC. youtu.be/loZSphK4s9g

reply retweet favorite
9:45 am · 2022-04-11
Twitter
EPAD
EPAD
@IMI_EPAD

We are delighted to announce that the first study participant for the @IMI_EPAD Scotland study was seen today! It is the first national initiative to have started study recruitment. @craig_ritchie68 @CenDemPrevent For more info, visit our website⤵️ ep-ad.org/first-national… pic.twitter.com/4Z46mokA88

reply retweet favorite
12:44 pm · 2022-04-07
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT